Two-month Regimens using novel Combinations to Augment Treatment effectiveness for drug-sensitive Tuberculosis: the "TRUNCATE-TB" trial.

Tuberculosis patients currently face a six-month daily pill regimen, and the TRUNCATE-TB trial tests whether two months of a novel drug combination, followed by re-treatment only if the disease returns, works just as well. This matters because the standard six-month treatment is a major global health burden—patients often stop taking pills early, fueling drug resistance, and the long duration strains already overstretched health systems in high-TB countries like those in Asia. The trial directly asks whether a shorter initial course can match the standard approach in clearing TB from sputum two years later, while also reducing costs, improving quality of life, and preventing resistance from emerging. If successful, this strategy could transform TB control. Clinics would need fewer patient visits and less medication stockpiling, freeing resources for other priorities. Patients would face a far more manageable treatment period, potentially boosting completion rates and cutting transmission. The trial also aims to build a sustainable Asian clinical trials network, enabling future studies of shorter TB regimens. While not fundamental science, this pragmatic trial could reshape how drug-sensitive TB is treated worldwide, making a proven cure faster and cheaper to deliver.